ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

AstraZeneca invests big in China

by Ryan Cross
November 17, 2019 | APPEARED IN VOLUME 97, ISSUE 45

 

09745-buscon15-astra.jpg
Credit: AstraZeneca
AstraZeneca's China headquarters in Shanghai

AstraZeneca is expanding its footprint and investment in China. The drugmaker is opening an AI Innovation Centre and a Global R&D Centre in Shanghai. The R&D site will focus on drug development for diseases common in China and other Asian countries. It will boost the firm’s R&D head count in Shanghai to about 1,000. AstraZeneca is also partnering with the investment bank China International Capital to create a $1 billion fund to invest in Chinese health-care companies and firms looking to expand in China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment